BBSRC Portfolio Analyser
Award details
Oral delivery of vaccine and therapeutic products using non-pathogenic lactic acid bacteria (LABDEL)
Reference
BBS/E/F/00041202
Principal Investigator / Supervisor
Dr Jerry Wells
Co-Investigators /
Co-Supervisors
Institution
Quadram Institute Bioscience
Department
Quadram Institute Bioscience Department
Funding type
Research
Value (£)
141,660
Status
Completed
Type
Institute Project
Start date
01/03/2001
End date
29/02/2004
Duration
36 months
Abstract
Scientific discoveries made in previous EC funded research programs on the lactic acid bacteria (LAB) have shown that there is considerable potential to develop products based on the oral delivery of vaccine and therapeutic agents using harmless commensal LAB. The aim is to harness this potential by developing and testing prototype LAB-based products for vaccination, prevention and treatment of type I allergy, treatment of a metabolic disorder and delivery of a therapeutic antioxidant. This multifaceted strategy for exploitation is underpinned by research on LAB fermentation and technological innovations that will enhance the efficiency of LAB delivery systems.
Summary
unavailable
Committee
Closed Committee - Agri-food (AF)
Research Topics
X – not assigned to a current Research Topic
Research Priority
X – Research Priority information not available
Research Initiative
X - not in an Initiative
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search